UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1048-15
Program Prior Authorization/Notification
Medications Besremi® (ropeginterferon alfa-2b-njft)
P&T Approval Date 2/2004, 7/2007, 4/2009, 12/2009, 9/2010, 9/2011, 8/2012, 11/2012,
4/2013, 2/2014, 4/2014, 5/2015, 11/2016, 11/2017, 11/2018, 11/2019,
11/2020, 11/2021, 1/2022, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Besremi (ropeginterferon alfa-2b-njft) is an interferon alfa-2b indicated for the treatment of
adults with polycythemia vera.2
2. Coverage Criteriaa:
A. Polycythemia Vera
1. Besremi will be approved based upon the following criterion:
a. Diagnosis of polycythemia vera
Authorization will be issued for 12 months.
B. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Accessed
September 6, 2024 at https://www.nccn.org/compendia-templates/compendia/nccn-
compendia
2. Besremi [package insert]. Burlington, MA: PharmaEssentia; April 2024.
Program Prior Authorization/Notification - Besremi
Change Control
4/2014 For Pegasys and Peg-Intron, added patients with chronic hepatitis C
genotype 3 as a patient population that may receive Sovaldi triple
therapy.
2/2014 Removed all age criteria. Added criteria for triple therapy regimen
including Olysio. Added criteria for triple therapy regimen including
Sovaldi. Added criteria for giant cell tumor of the bone.
5/2015 Revised criteria for treatment of hepatitis C given market removal of
Incivek, Infergen and pending removal of Victrelis. Criteria now
reflects the shift in treatment of hepatitis C to non-interferon based
therapies.
6/2015 Administrative change. Documented approval period for Pegasys
“other indications”
11/2016 Annual review. Consolidation of hepatitis B and C criteria. Updated
off-label NCCN recommendations for use. Updated references.
11/2017 Annual review. Updated off-label NCCN recommendations for use.
Removed CML (Intron A, Pegasys, Pegintron) and systemic light chain
amyloidosis (Intron A) indications as no longer rec by NCCN. Updated
references.
11/2018 Annual review. Updated background and criteria to include NCCN
recommended use for systemic mastocytosis. Updated references.
11/2019 Annual review. Added general NCCN recommendations for use
criteria. Updated references.
11/2020 Annual review. Updated background and criteria to include NCCN
recommendations. Updated references.
11/2021 Annual review. Removed discontinued products, PegIntron and
Sylatron. Updated background and criteria to align with label and
NCCN guidelines. Updated references.
1/2022 Added criteria for Besremi. Updated references.
10/2022 Removed Intron A and Pegasys from program, including updates to
background, criteria, and references. Added state mandate.
10/2023 Annual review without changes to criteria. Updated references.
10/2024 Annual review without changes to criteria. Updated references.
© 2024 UnitedHealthcare Services, Inc.
2